➡️ Language: English
➡️ Duration: 37 min
➡️ Presenter: Prof. MEHMET UMUT AKYOL, Hacettepe University, Turkey
➡️ Presenter: Dr MATTHIAS SCHAFER, Acura-Kliniken, Albstadt, Germany
Learning Objectives: PART 1 - OTORHINOLARYNGOLOGY: (1) Gain awareness about the main otorhinolaryngological presenting signs of mucopolysaccharidoses and Alpha-mannosidosis and their time of show-up. (2) Recognize the challenges and dangers of surgical treatment of patients with mucopolysaccharidosis and Alpha-mannosidosis. (3) An overview of the other Otorhinolaryngological presenting symptoms of MPS and Alpha-mannosidosis and recommendations about the timing of treatment, treatment/consultation options. PART 2 - ANAESTHESIOLOGY: (1) Gain awareness about the adequate perioperative workup of severe phenotype MPS-patients. (2) Recognize the challenges and dangers of anaesthesia management of patients with MPS (3) An overview of main MPS symptoms influencing anaesthesia and postoperative care and recommendations for management.
Mehmet Umut Akyol is Professor of Otorhinolaryngology, Hacettepe University, Turkey
Matthias K. Schaefer is working in the Clinic for Anesthesia, Intensive Care, Emergency Medicine and Pain Therapy, Acura-Kliniken, Albstadt, Germany. Honorary Clinical Lecturer at the University Medical School of Mainz, Mainz, Germany and the University of Jena, Germany.
Important Note: The information provided on this session is intended and designed for use by healthcare professionals with an interest in metabolic diseases, MPS and alpha-mannosidosis. All session viewers are required to register for the selected webinar before accessing the content. Content and views shared are solely those of the speaker.
The free-to-attend online course has been designed to help specialists and general paediatricians to reduce delay in the referral and diagnosis of patients with suspected MPS and alpha-mannosidosis, as well as improving the quality of patient’s lives who have already been diagnosed. On-time diagnosis is crucial for access to treatment and clinical trials, disease management and to access the proper care services at the earliest of the disease possible.
The course is an MPS Europe project in partnership with MetabERN and the Excellence in Pediatrics with the support of Abeona, Biomarin, Chiesi, Orchard Therapeutics, Regenxbio, Sanofi Genzyme, Takeda, and Ultragenyx. All modules of the course are independently organised by EIP in terms of content, topics and speakers appointed.